Hepatotoxicity of Camptothecin Derivatives in a Primary Culture System of Rat Hepatocytes
- 1 January 2000
- journal article
- Published by Taylor & Francis in Journal of Chemotherapy
- Vol. 12 (4) , 345-351
- https://doi.org/10.1179/joc.2000.12.4.345
Abstract
The topoisomerase I inhibitors are a new class of antineoplastic agents currently under clinical development. Among these compounds there are some camptothecin (CPT) derivatives with improved toxicity profiles and antitumor activity: irinotecan (CPT-11) and topotecan (TPT), particularly active against colon, lung and ovarian cancer. The aim of this study was to evaluate the cytotoxicity of CPT, CPT-11, its metabolite SN38 and TPT in a primary culture system of rat hepatocytes. Cytotoxicity was evaluated by measuring the leakage of lactate dehydrogenase (LDH) into the medium and by assessing cell viability in terms of tetrazolium salts (MTT) reduction by mitochondrial dehydrogenase activity. Our results showed that cytotoxicity was limited in the case of short drug exposure. There was a significant and time-dependent increase in LDH leakage and a significant time- and dose-dependent decrease in MTT reduction after 3 h of incubation (p<0.01). In the treatments with doses related to peak plasma levels, CPT-11 was less responsible for the observed in vitro hepatotoxicity than its metabolite SN38; TPT had lower LDH leakage compared to SN38 and CPT-11 but showed significant and early (3 h) decrease in MTT reduction: this may mean a different mechanism of cellular damage. These results demonstrate that CPT derivatives are directly toxic to liver cells in a distinct time- and dose-related response.Keywords
This publication has 10 references indexed in Scilit:
- No Alteration in DNA Topoisomerase I Gene Related to CPT‐11 Resistance in Human Lung CancerJapanese Journal of Cancer Research, 1996
- Rationale for the dosage and schedule of CPT-11 (irinotecan) selected for phase II studies, as determined by European phase I studiesAnnals of Oncology, 1996
- Clinical Pharmacokinetics of TopotecanClinical Pharmacokinetics, 1996
- Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trialsAnnals of Oncology, 1995
- Pharmacokinetics of SN-38 ((+)-(4S)-4,11-Diethyl-4,9-dihydroxy-1H-pyrano(3',4':6,7)-indolizino(1,2-b)quinoline-3,14(4H,12H)-dione), an Active Metabolite of Irinotecan, after a Single Intravenous Dosing of 14C-SN-38 to Rats.Biological & Pharmaceutical Bulletin, 1995
- Comparison of Topoisomerase I Inhibition, DNA Damage, and Cytotoxicity of Camptothecin Derivatives Presently in Clinical TrialsJNCI Journal of the National Cancer Institute, 1994
- Topoisomerase I inhibitors: topotecan and irenotecanCancer Treatment Reviews, 1994
- An in vitro approach to the study of target organ toxicity of drugs and chemicalsIn Vitro Cellular & Developmental Biology, 1985
- Correlations of in vitro and in vivo hepatotoxicity for five haloalkanesToxicology and Applied Pharmacology, 1983
- Preparation of rat liver cellsExperimental Cell Research, 1973